As previously disclosed, Vir Biotechnology, Inc. (the ?Company?) and Glaxo Wellcome UK Limited (?GSK? and, together with the Company, the ?Parties?) entered into a Definitive Collaboration Agreement on May 18, 2021 (the ?DCA?). Under the terms of the DCA, the Parties agreed to collaborate on three separate programs, among them a program to research, develop and commercialize the Company?s monoclonal antibodies for the prevention, treatment or prophylaxis of the influenza virus (such program, the ?Influenza Program?).

On February 21, 2024, the Parties entered into a letter agreement (the ?Letter Agreement?) pursuant to which the Parties mutually agreed to terminate their collaboration on the Influenza Program under the DCA. More specifically, pursuant to the Letter Agreement, (i) all influenza products included within the Influenza Program which, as of February 21, 2024, included VIR-2482XX2 (also known as VIR-2372) and VIR-2981 (the ?Existing Terminated Influenza Products?), are removed from the scope of the DCA, (ii) the Company?s exclusivity obligations to GSK under the DCA with respect to the Influenza Program are terminated and of no further force or effect, (iii) GSK?s option to VIR-2482 is terminated and of no further force or effect and the Company will have no further obligations to GSK with respect to VIR-2482, (iv) the Company will make payments of tiered royalties to GSK on net sales of any Existing Terminated Influenza Products, and variants or improvements thereof, in the low single digits, subject to certain deductions in certain circumstances, (v) the Company will have no further obligations to GSK with respect to any Existing Terminated Influenza Product or variants or improvements thereof (other than commercially reasonable efforts to develop and commercialize Existing Terminated Influenza Products or variants or improvement thereof in Major Markets (as defined in the DCA)), and (vi) the Company shall have the right to further develop and commercialize VIR-2482 or any Existing Terminated Influenza Product, and variants or improvements thereof, independently, alone, or via an affiliate or with a third party, in any case without restriction. The Letter Agreement also includes certain clarifications and terminations of specific provisions of the DCA in light of the termination of the collaboration on the Influenza Program, including provisions relating to the Parties?

opt-out rights, as well other matters relating to the transfer of technology, materials, documentation and existing manufacturing commitments.